Kairos Pharma, Ltd.
Records under this name other than the patents Kairos Pharma, Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Showing 1 to 5 of 5 · Back to Kairos Pharma, Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,336,831 | Use of anti-endoglin antibodies for treating ocular fibrosis Lapsed on the fee record Ended Jul 2, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jul 2, 2023 | From the USPTO record |
| US 10,155,820 | Anti-endoglin antibodies and uses thereof Lapsed on the fee record Ended Dec 18, 2022 · From the USPTO record | Lapsed on the fee record | Ended Dec 18, 2022 | From the USPTO record |
| US 9,926,375 | Anti-endoglin antibodies and uses thereof Lapsed on the fee record Ended Mar 27, 2022 · From the USPTO record | Lapsed on the fee record | Ended Mar 27, 2022 | From the USPTO record |
| US 8,609,094 | Endoglin antibodies Lapsed on the fee record Ended Dec 17, 2021 · From the USPTO record | Lapsed on the fee record | Ended Dec 17, 2021 | From the USPTO record |
| US 9,518,122 | Endoglin antibodies Lapsed on the fee record Ended Dec 13, 2020 · From the USPTO record | Lapsed on the fee record | Ended Dec 13, 2020 | From the USPTO record |